Functional involvement of central cholinergic circuits and visual hallucinations in Parkinsons disease

Brain

Volumn 132, Issue 9, 2009, Pages 2350-2355

  Manganelli, Fiore ^a   Vitale, Carmine ^a,b,c   Santangelo, Gabriella ^a,c,d   Pisciotta, Chiara ^a   Iodice, Rosa ^a   Cozzolino, Autilia ^a   Dubbioso, Raffaele ^a   Picillo, Marina ^a   Barone, Paolo ^a   Santoro, Lucio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^c Istituto di Diagnosi e Cura Hermitage Capodimonte   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cognitive deficits; Parkinsons disease; Short latency afferent inhibition; TMS; Visual hallucinations

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ARTICLE; ATTENTION; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EVOKED MUSCLE RESPONSE; FEMALE; FOLLOW UP; FRONTAL LOBE; HUMAN; MALE; MEMORY; MOTOR CORTEX; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; SOMATOSENSORY CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL HALLUCINATION;

EID: 71549158572     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp166     Document Type: Article

References (45)

1. Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61: 1906-1911.
2. Aarsland D, Brønnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42.
3. Asahina M, Shinotoh H, Hirayama K, Suhara T, Shishido F, Inoue O, et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol Scand 1995; 91: 437-443.
4. Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, Capitani E. A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci 1998; 19: 161-170.
5. Barnes J, Boubert L, Harris J, Lee A, David AS. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia 2003; 41: 565-574.
6. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and Parkinsonian dementia. J Neurol 2006; 253: 242-247.
7. Bosboom JL, Stoffers D, Wolters ECh. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004; 111: 1303-1315.
8. Brandstaedter D, Spieker S, Ulm G, Siebert U, Eichhorn TE, Krieg JC, et al. Development and evaluation of the Parkinson Psychosis Questionnaire: A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. J Neurol 2005; 252: 1060-1066.
9. Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 2002; 22: 443-447. (Pubitemid 34436807)
10. Caltagirone C, Gainotti G, Fasullo C, Miceli G. Validity of some neuropsychological test in the assessment of mental deterioration. Acta Psychiatr Scand 1979; 60: 50-56.
11. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-1277.
12. Chen R, Cros D, Curra A, Di Lazzaro V, Lefaucheur JP, Magistris MR, et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2008; 119: 504-532.
13. Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Bentivoglio AR, et al. Normal or enhanced short-latency afferent inhibition in Parkinson's disease? Brain 2004a; 127: E8.
14. Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Marra C, et al. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004b; 75: 555-559. (Pubitemid 38406651)
15. Di Lazzaro V, Oliviero A, Profice P, Pennisi MA, Di Giovanni S, Zito G, et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res 2000; 135: 455-461.
16. Di Lazzaro V, Oliviero A, Saturno E, Dileone M, Pilato F, Nardone R, et al. Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans. J Physiol 2005; 564: 661-668. (Pubitemid 40585061)
17. Di Lazzaro V, Oliviero A, Tonali PA, Marra C, Daniele A, Profice P, et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 2002; 59: 392-397.
18. Di Lazzaro V, Pilato F, Dileone M, Saturno E, Oliviero A, Marra C, et al. In vivo cholinergic circuit evaluation in frontotemporal and Alzheimer dementias. Neurology 2006; 66: 1111-1113.
19. Di Lazzaro V, Pilato F, Dileone M, Saturno E, Profice P, Marra C, et al. Functional evaluation of cerebral cortex in dementia with Lewy bodies. NeuroImage 2007; 37: 422-429.
20. Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol 1997; 48: 649-684.
21. Fénelon G, Mahieux F, Huon R, Zié gler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-745.
22. Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriatr Psychiatry 2005; 20: 668-673.
23. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-1722.
24. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19: 1043-1049.
25. Inglis WL, Olmstead MC, Robbins TW. Selective deficits in attentional performance on the 5-choice serial reaction time task following pedunculopontine tegmental nucleus lesions. Behav Brain Res 2001; 123: 117-131.
26. Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 1993; 60: 197-203.
27. Londos E, Passant U, Risberg J, Gustafson L, Brun A. Contributions of other brain pathologies in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002; 13: 130-148.
28. Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 178-183.
29. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998; 121: 1819-1840.
30. Manganelli F, Ragno M, Cacchiò G, Iodice V, Trojano L, Silvaggio F, et al. Motor cortex cholinergic dysfunction in CADASIL: a transcranial magnetic demonstration. Clin Neurophysiol 2008; 119: 351-355.
31. Milner B. Effect of different brain lesions on card sorting. Arch Neurol 1963; 9: 100-110.
32. Mondini S, Mapelli D, Vestri A, Bisiacchi PS. Esame neuropsicologico breve: una batteria di test per lo screening neuropsicologico. Milano: Raffaello Cortina Editore 2003.
33. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human choli-nergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 2003; 26: 233-242.
34. Nardone R, Florio I, Lochner P, Tezzon F. Cholinergic cortical circuits in Parkinson's disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study. Exp Brain Res 2005; 163: 128-131.
35. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005; 65: 1708-1715.
36. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22: 273-280.
37. Ruberg M, Ploska A, Javoy-Agid F, Agid Y. Muscarinic binding and choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res 1982; 232: 129-139.
38. Sailer A, Molnar GF, Paradiso G, Gunraj CA, Lang AE, Chen R. Short and long latency afferent inhibition in Parkinson's disease. Brain 2003; 126: 1883-1894.
39. Sakuma K, Murakami T, Nakashima K. Short latency afferent inhibition is not impaired in mild cognitive impairment. Clin Neurophysiol 2007; 118: 1460-1463.
40. Santangelo G, Trojano L, Vitale C, Ianniciello M, Amboni M, Grossi D, et al. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Mov Disord 2007; 22: 2418-2425.
41. Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998; 121: 2249-2257.
42. Sirvio J, Rinne JO, Valjakka A, Rinne UK, Riekkinen PJ, Paljarvi L. Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson's disease. J Neurol Sci 1989; 90: 23-32.
43. Spinnler H, Tognoni G. Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 1987; 8: 1-120.
44. Tokimura H, Di Lazzaro V, Tokimura Y, Oliviero A, Profice P, Insola A, et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol 2000; 523: 503-513.
45. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology 2005; 65: 1907-1913